These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16278277)

  • 1. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
    Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
    Am J Physiol Renal Physiol; 2006 Apr; 290(4):F813-20. PubMed ID: 16278277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy.
    Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
    Am J Nephrol; 2006; 26(1):50-8. PubMed ID: 16508247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice.
    Wang LH; Liu JS; Ning WB; Yuan QJ; Zhang FF; Peng ZZ; Lu MM; Luo RN; Fu X; Hu GY; Wang ZH; Tao LJ
    Pharmacology; 2011; 88(1-2):88-99. PubMed ID: 21847000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid hormone ameliorates diabetic nephropathy in a mouse model of type II diabetes.
    Lin Y; Sun Z
    J Endocrinol; 2011 May; 209(2):185-91. PubMed ID: 21307121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice.
    Ichinose K; Maeshima Y; Yamamoto Y; Kinomura M; Hirokoshi K; Kitayama H; Takazawa Y; Sugiyama H; Yamasaki Y; Agata N; Makino H
    Diabetes; 2006 May; 55(5):1232-42. PubMed ID: 16644677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice.
    Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
    Nephron Exp Nephrol; 2007; 105(2):e45-52. PubMed ID: 17139189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMP-534 inhibits TGF-beta-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis.
    Sugaru E; Sakai M; Horigome K; Tokunaga T; Kitoh M; Hume WE; Nagata R; Nakagawa T; Taiji M
    Am J Physiol Renal Physiol; 2005 Nov; 289(5):F998-1004. PubMed ID: 15900023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
    Mizuno S; Nakamura T
    Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
    Ziyadeh FN; Hoffman BB; Han DC; Iglesias-De La Cruz MC; Hong SW; Isono M; Chen S; McGowan TA; Sharma K
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):8015-20. PubMed ID: 10859350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice.
    Dai C; Yang J; Bastacky S; Xia J; Li Y; Liu Y
    J Am Soc Nephrol; 2004 Oct; 15(10):2637-47. PubMed ID: 15466268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble betaglycan reduces renal damage progression in db/db mice.
    Juárez P; Vilchis-Landeros MM; Ponce-Coria J; Mendoza V; Hernández-Pando R; Bobadilla NA; López-Casillas F
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F321-9. PubMed ID: 16954341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
    J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency.
    Cohen MP; Lautenslager GT; Hud E; Shea E; Wang A; Chen S; Shearman CW
    Am J Physiol Renal Physiol; 2007 Feb; 292(2):F789-95. PubMed ID: 17018845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of C-peptide on early glomerular changes in diabetic mice.
    Maezawa Y; Yokote K; Sonezaki K; Fujimoto M; Kobayashi K; Kawamura H; Tokuyama T; Takemoto M; Ueda S; Kuwaki T; Mori S; Wahren J; Saito Y
    Diabetes Metab Res Rev; 2006; 22(4):313-22. PubMed ID: 16389646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
    Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
    J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice.
    Cohen MP; Lautenslager GT; Shearman CW
    Metabolism; 2001 Dec; 50(12):1435-40. PubMed ID: 11735089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halofuginone prevents extracellular matrix deposition in diabetic nephropathy.
    Sato S; Kawamura H; Takemoto M; Maezawa Y; Fujimoto M; Shimoyama T; Koshizaka M; Tsurutani Y; Watanabe A; Ueda S; Halevi K; Saito Y; Yokote K
    Biochem Biophys Res Commun; 2009 Feb; 379(2):411-6. PubMed ID: 19114027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.